PC5-52-P-L-D

PC5-52-P-L-D is a peptide-based inhibitor of proprotein convertase 5/6 (PC5/6), also known as PCSK5, developed by researchers at the Burnet Institute. PC5/6 is a member of the proprotein convertase family responsible for the proteolytic activation of various precursor proteins into their biologically active forms. In the context of HIV-1 infection, PC5/6 is required for the processing of the viral envelope glycoprotein gp160 into its functional subunits, gp120 and gp41, which are essential for viral entry into host cells. PC5-52-P-L-D is designed as a topical vaginal microbicide to block this activation, thereby preventing HIV-1 transmission. Additionally, PC5/6 plays a critical role in the female reproductive tract by regulating uterine receptivity and embryo implantation. Consequently, PC5-52-P-L-D is also being investigated for its potential as a non-hormonal contraceptive or for managing implantation-related disorders. The 'P-L-D' designation refers to structural modifications—PEGylation, a Linker, and the incorporation of D-amino acids—intended to improve the peptide's stability and efficacy in the vaginal environment.